Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JUNE 2017. Refer to TA459: Collagenase clostridium histolyticum for treating Dupuytren's contracture for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | collagenase Clostridium histolyticum (Xiapex®) | ||
| Formulation | 0.9 mg powder and solvent for solution for injection | ||
| Reference number | 930 | ||
| Indication | Treatment of Dupuytren’s contracture in adult patients with a palpable cord |
||
| Company | Swedish Orphan Biovitrum Ltd | ||
| BNF chapter | Musculoskeletal & joint diseases | ||
| Submission type | Full | ||
| Status | Superseded | ||
| Advice number | 1711 | ||
| NMG meeting date | 05/10/2011 | ||
| AWMSG meeting date | 09/11/2011 | ||
| Ratification by Welsh Government | 20/12/2011 | ||
| Date of issue | 12/01/2012 | ||
| NICE guidance | TA459: Collagenase clostridium histolyticum for treating Dupuytren's contracture (external website - opens in new window) |
||